In July, Medicare proposed to start paying for some mental health apps, in a move applauded by the developers of those treatments after years of struggling to find adoption among clinicians and patients.
But it wasn’t only the startups and their supporters that took notice — some of the largest pharma and health care companies in the country, like Pfizer and CVS Health, weighed in on the proposal during the comment period, arguing for modifications that suit their vision for how digital treatments ought to be valued. The comments, especially from the large pharmaceutical companies and insurers, underscore how Medicare’s decisions could help define how the health care system pays for emerging technologies.
Andy Molnar, CEO of the Digital Therapeutics Alliance, the advocacy group for developers, told STAT that this experiment could result in important learnings for the Centers for Medicare and Medicaid Services about how coverage of software medical devices translates to costs, provider adoption, and patient access.
